Near-final height outcomes in children with idiopathic short stature responsive to the IGF-1 generation test: a multicenter retrospective study of rhGH therapy.

What Was Tested

This observational study looks at IGF-1 LR3.

The aim of this study was to describe near-final height (NFH) outcomes and to identify clinical predictors of growth response in children with ISS who were selected for rhGH therapy based on a positive IGF-1 generation test (IGFGT).

Why It Was Studied

Selecting appropriate candidates for recombinant human growth hormone (rhGH) therapy remains challenging.

Who Took Part

The study group was 14 girls.

PubMed indexes the participants as children and teenagers, both men and women.

How the Study Was Run

The researchers set it up as a multicenter study.

More than one site took part, so the girls came from several places.

GH1 gene sequencing was performed to exclude biologically inactive GH, a condition marked by normal or elevated GH secretion but impaired biological activity.

NFH was defined as bone age ≥ 14 years in girls and ≥ 16 years in boys.

Height SDS gain from baseline to NFH was evaluated.

What Was Measured

The subject headings attached to it are Body Height, Dwarfism, Growth Disorders, Human Growth Hormone, Insulin-Like Growth Factor I, Prognosis and Recombinant Proteins.

Author keywords: GH1 gene variation, Growth hormone treatment, Growth velocity, Idiopathic short stature, Insulin-like growth factor-1 generation test (IGFGT) and Near-final height.

What This Means in Plain Language

The paper is a multicenter study of IGF-1 LR3 in 14 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (BMC endocrine disorders), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.